The concept of monoclonal antibody-directed cancer therapy is exemplified by trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) receptor and a mainstay of anti-HER2-directed therapy for breast cancer [2]. Here, ERBB2 is linked to cancer.